Emerging Targeted Immunotherapies Show Promise for Graves' Disease Beyond Standard Antithyroid Drugs

Graves' disease is an autoimmune condition in which TSH receptor autoantibodies (TRAb) stimulate the thyroid gland, leading to hyperthyroidism and, in many patients, extrathyroidal manifestations such as thyroid eye disease and pretibial myxedema. Standard first-line treatment with antithyroid drugs controls hyperthyroidism but carries a high relapse rate of 50 to 60% after drug discontinuation. Definitive treatments including radioiodine therapy and thyroidectomy permanently ablate the thyroid but do not address the underlying autoimmune process.

This review evaluates targeted immunotherapies in early-phase clinical development for Graves' thyroidal and orbital disease, including anti-CD20 B-cell depletion with rituximab, anti-CD40 blockade with iscalimab, and antigen-specific immunotherapy approaches. In a phase 2 proof-of-concept trial, iscalimab induced normalization of thyroid function in 47% of patients at 24 weeks and markedly reduced TRAb levels. Rituximab has demonstrated ability to sustain remission in combination with antithyroid drugs, transitioning from experimental to clinically viable use in refractory cases.

Other agents under active investigation include FcRn inhibitors that accelerate pathogenic IgG clearance, TSH receptor antagonists, and immune tolerance induction strategies. While most existing trial data come from open-label phase 1 and 2 studies, the accumulating evidence points toward a near-future paradigm shift in Graves' disease management toward targeted immunomodulation that preserves thyroid function while addressing the autoimmune etiology.